Self-emulsifying O/W formulations of paclitaxel prepared from mixed nonionic surfactants

Journal of Pharmaceutical Sciences

Volumn 99, Issue 5, 2010, Pages 2320-2332

  Lo, Jen Ting ^a   Chen, Bing Hung ^a   Lee, Tzer Min ^a   Han, Jun ^b   Li, Jing Liang ^b,c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Biocompatibility; Drug delivery; Emulsion microemulsion; Formulation vehicle; Micelle; Microencapsulation; Paclitaxel; Self emulsifying; Surfactant

Indexed keywords

2 PHENYLETHANOL BENZYL BENZOATE; BENZYL ALCOHOL; BENZYL BENZOATE; CREMOPHORE; DILUENT; NONIONIC SURFACTANT; OIL; PACLITAXEL; PHOSPHATIDYLCHOLINE; POLYSORBATE 80; SORBITAN OLEATE; TRIBUTYRIN; UNCLASSIFIED DRUG; WATER;

ANIMAL CELL; AQUEOUS SOLUTION; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; CYTOTOXICITY; DILUTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; EGG YOLK; EMULSION; INJECTION; LIQUID; NONHUMAN; PRECIPITATION; SELF EMULSIFYING;

EID: 77951278963     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21993     Document Type: Article

References (32)

1. Ojima I, Das M. 2009. Recent advances in the chemistry and biology of new generation taxoids. J Nat Prod 72:554-565
2. Steed H, Sawyer MB. 2007. Pharmacology, pharmacokinetics and pharmacogenomics of paclitaxel. Pharmacogenomics 8: 803-815
3. Hennenfent KL, Govindan R. 2006. Novel formulations of taxanes: A review. Old wine in a new bottle? Ann Oncol 17: 735-749
4. Han J, Davis ST, Papandreou C, Melia CD, Washington C. 2004. Design and evaluation of an emulsion vehicle for paclitaxel. I. Physiochemical properties and plasma stability. Pharm Res 21:1573-1579
5. Konno T, Watanabe J, Ishihara K. 2003. Enhanced solubility of paclitaxel using water-soluble and biocompatible 2-methacryloyloxyethyl phosphorylcholine polymers. J Biomed Mater Res A 65A:209-214 (Pubitemid 37521427)
6. Taxol® (paclitaxel) injection, Bristol-Myers Squibb Company, Princeton, NJ, 2003
7. Gao P, Rush BD, Pfund WP, Huang TH, Bauer JM, Morozowich W, Kuo MS, Hageman MJ. 2003. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci 92:2386-2398 (Pubitemid 37484765)
8. Feng SS, Zhao L, Zhang Z, Bhakta G, Win KY, Dong Y, Chien S. 2007. Chemotherapeutic engineering: Vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168 h in vivo. Chem Eng Sci 62:6641-6648 (Pubitemid 47610671)
9. Yang R, Yang SG, Shim WS, Cui FD, Cheng G, Kim IW, Kim DD, Chung SJ, Shim CK. 2009. Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates. J Pharm Sci 98:970-984
10. D'Souza GGM, Wang T, Rockwell K, Torchilin VP. 2008. Surface modification of pharmaceutical nanocarriers with ascorbate residues improves their tumor-cell association and killing and the cytotoxic action of encapsulated paclitaxel in vitro. Pharm Res 25:2567-2572
11. Bilensoy E, Gurkaynak O, Ertan M, Sen M, Hincal AA. 2008. Development of nonsurfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel. J Pharm Sci 97:1519-1529
12. Danhier F, Lecouturier N, Vroman B, Jérôme C, Marchand-Brynaert J, Feron O, Préat V. 2009. Paclitaxel-loaded PEGy-lated PLGA-based nanoparticles: In vitro and in vivo evaluation. J Controlled Release 133:11-17
13. Forrest ML, Yanez JA, Remsberg CM, Ohgami Y, Kwon GS, Davies NM. 2008. Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelle nanocarriers: Pharmacokinetic disposition, tolerability, and cytotoxicity. Pharm Res 25:194-206
14. Chun C, Lee SM, Kim SY, Yang HK, Song SC. 2009. Thermosensitive poly(organophosphazene)-paclitaxel conjugate gels for antitumor applications. Biomaterials 30:2349-2360
15. Suffness M. 1995. Taxol 1: Science and applications. Boca Raton, FL: CRC Press
16. Zhang ZP, Lee SH, Feng SS. 2007. Folate-decorated poly(lactide-co- glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. Biomaterials 28:1889-1899 (Pubitemid 46137995)
17. Sun B, Ranganathan B, Feng SS. 2008. Multifunctional poly(D,L-lactide-co- glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials 29:475-486 (Pubitemid 350110345)
18. Tarr BD, Sambandan TG, Yalkowsky SH. 1987. A new parenteral emulsion for the administration of Taxol. Pharm Res 4:162-165
19. Kan P, Chen ZB, Lee CJ, Chu IM. 1999. Development of nonionic surfactant/phospholipid O/W emulsion as a paclitaxel delivery system. J Controlled Release 58:271-278 (Pubitemid 29142451)
20. Kan P, Chen ZB, Kung RY, Lee CJ, Chu IM. 1999. Study on the formulation of O/W emulsion as carriers for hydrophobic drugs. Colloids Surf B 15:117-125 (Pubitemid 29393106)
21. Simamora P, Dannefelser R, Tabib SE, Yalkowsky SH. 1998. Emulsion formulation for intravenous administration of paclitaxel. PDA J Pharm Sci Technol 52:170-172 (Pubitemid 28427711)
22. Bartoli H, Boitard M, Fessi H, Beriel H, Devissagnet JP, Picot F, Puisien F. 1990. In vitro and in vivo antitumoral activity of free and encapsulated Taxol. J Microencapsul 7:191-197
23. Chen ZX, Breitman TR. 1994. Tributyrin: A prodrug of butyric acid for potential clinical application in differentiation therapy. Cancer Res 54:3494-3499
24. Hammad MA, Müller BW. 1998. Increasing drug solubility by means of bile salt-phosphatidylcholine-based mixed micelles. Eur J Pharm Biopharm 46:361-367
25. Liu D, Mori A, Huang L. 1991. Large liposomes containing gangloiside gm1 accumulate effectively in spleen. Biochim Biophys Acta 1066:159-165
26. Nagayasu A, Uchiyama K, Kiwada H. 1999. The size of liposomes: A factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Deliver Rev 40:75-87 (Pubitemid 29486605)
27. Rosen MJ. 2004. Surfactant and interfacial phenomena, 3rd edition. New York: Wiley. Chapter 8
28. Vaughan CD, Rice DA. 1990. Predicting O/W emulsion stability by the "Required HLB Equation". J Disper Sci Technol 11: 83-91
29. Woodcock DM, Linsenmeyer ME, Chojnowski G, Kriegler AB, Nink V, Webster LK, Sawyer WH. 1992. Reversal of multidrug resistance by surfactants. Br J Cancer 66: 62-68
30. Andersson BJ. 1999. Parenteral paclitaxel in a stable non-toxic formulation, US Patent 5,877,205
31. Takahashi H, Niidome Y, Niidome T, Kaneko K, Kawasaki H, Yamada S. 2006. Modification of gold nanorods using phospatidylcholine to reduce cytotoxicity. Langmuir 22: 2-5 (Pubitemid 43063513)
32. Savic S, Weber C, Tamburic S, Savic M, Müller-Goymann C. 2009. Topical vehicles based on natural surfactant/fatty alcohols mixed emulsifier: The influence of two polyols on the colloidal structure and in vitro/in vivo skin performance. J Pharm Sci 98:2073-2090